Decheng Capital’s Krystal Biotech KRYS Stock Holding History

Decheng Capital’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,300	Closed	-$1.89M	–	15
2026 Q1	$1.89M	Sell	7,300 -10,000	-58%	-$2.66M	0.29%	13
2025 Q4	$4.27M	Sell	17,300 -15,000	-46%	-$3.16M	0.57%	13
2025 Q3	$5.7M	Sell	32,300 -33,700	-51%	-$5.04M	0.99%	14
2025 Q2	$9.07M	Buy	66,000 +1,000	+2%	+$147K	2.29%	8
2025 Q1	$11.7M	Sell	65,000 -11,772	-15%	-$1.98M	3.29%	6
2024 Q4	$12M	Buy	76,772 +5,000	+7%	+$887K	2.58%	7
2024 Q3	$13.1M	Buy	71,772 +6,000	+9%	+$1.16M	3.09%	5
2024 Q2	$12.1M	Hold	65,772	–	–	3.7%	5
2024 Q1	$11.7M	Hold	65,772	–	–	1.57%	7
2023 Q4	$8.16M	Buy	+65,772	New	+$7.29M	2.28%	12

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Decheng Capital's KRYS Position: Q2 2026 in Review

Decheng Capital sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 7,300 shares — an estimated $1.89M sold.

Decheng Capital first reported a position in KRYS in Q4 2023 and held it in 10 quarters. The position peaked at $13.1M in Q3 2024. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Decheng Capital reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
Decheng Capital sold 7,300 Krystal Biotech shares in Q2 2026, an estimated $1.89M.
Decheng Capital first reported a position in Krystal Biotech in Q4 2023 and held it in 10 quarters.
Decheng Capital's Krystal Biotech position peaked at $13.1M in Q3 2024.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Decheng Capital's 13F filing for Q2 2026, filed 14 Aug 2026.